{
  "id": 4788898,
  "title": "Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays",
  "url": "https://urgent.news/2026/09/01/fujirebio-expands-access-in-canada-to-blood-based-neurology-testing",
  "topic": "culture",
  "section": "Culture",
  "published": "2026-09-01T05:04:33.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/fujirebio-expands-access-in-canada-to-blood-based-neurology-testing-with-health-canada-class-ii-medical-device-licenses-for-the-lumipulse-g-nfl-blood-and-lumipulse-g-ptau-217-plasma-assays"
  },
  "original_language": "en",
  "account": null,
  "summary": "GHENT, Belgium & TOKYO — H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}